Weisser M - Search Results

1

New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. Schnittger S, et al. Among authors: weisser m. Blood. 2003 Oct 15;102(8):2746-55. doi: 10.1182/blood-2003-03-0880. Epub 2003 Jul 3. Blood. 2003. PMID: 12842988 Free article.

2

The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.

Elsässer A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G. Elsässer A, et al. Among authors: weisser m. Oncogene. 2003 Aug 28;22(36):5646-57. doi: 10.1038/sj.onc.1206673. Oncogene. 2003. PMID: 12944913

3

Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy.

Weisser M, Kern W, Schoch C, Hiddemann W, Haferlach T, Schnittger S. Weisser M, et al. Haematologica. 2005 Jul;90(7):881-9. Haematologica. 2005. PMID: 15996925

4

Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).

Bacher U, Schnittger S, Kern W, Trenn G, Weisser M, Haferlach T, Schoch C. Bacher U, et al. Among authors: weisser m. Cancer Genet Cytogenet. 2006 Jul 15;168(2):172-4. doi: 10.1016/j.cancergencyto.2006.02.011. Cancer Genet Cytogenet. 2006. PMID: 16843110

5

Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases.

Weisser M, Haferlach C, Haferlach T, Schnittger S. Weisser M, et al. Cancer Genet Cytogenet. 2007 Aug;177(1):64-9. doi: 10.1016/j.cancergencyto.2007.05.003. Cancer Genet Cytogenet. 2007. PMID: 17693194

6

Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.

Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, Schnittger S. Weisser M, et al. Leukemia. 2005 Aug;19(8):1416-23. doi: 10.1038/sj.leu.2403809. Leukemia. 2005. PMID: 15920493

7

The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.

Weisser M, Haferlach C, Hiddemann W, Schnittger S. Weisser M, et al. Leukemia. 2007 Jun;21(6):1177-82. doi: 10.1038/sj.leu.2404659. Epub 2007 Mar 22. Leukemia. 2007. PMID: 17377588 Clinical Trial.

8

A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.

Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ. Weisser M, et al. Haematologica. 2006 May;91(5):663-6. Epub 2006 Apr 19. Haematologica. 2006. PMID: 16627251

9

Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia.

Weisser M, Kern W, Schoch C, Tschulik C, Hiddemann W, Haferlach T, Schnittger S. Weisser M, et al. Leuk Lymphoma. 2006 Dec;47(12):2645-7. doi: 10.1080/10428190600942561. Leuk Lymphoma. 2006. PMID: 17169810 No abstract available.

10

Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.

Weisser M, Haferlach C, Haferlach T, Schnittger S. Weisser M, et al. Leuk Lymphoma. 2007 Nov;48(11):2145-51. doi: 10.1080/10428190701632848. Leuk Lymphoma. 2007. PMID: 17926191

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

301 results

Search Page

Filters